TLP Group’s Spyre Therapeutics SYRE Stock Holding History

TLP Group’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-477	Closed	-$76K	–	372
2016 Q3	$76K	Buy	+477	New	+$66.4K	0.08%	231

Other funds holding SYRE

Jennison Associates

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Alyeska Investment Group

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

TLP Group's SYRE Position: Q4 2016 in Review

TLP Group sold out of Spyre Therapeutics (SYRE) in Q4 2016, closing a stake of 477 shares — an estimated $76K sold.

TLP Group first reported a position in SYRE in Q3 2016 and held it in 1 quarter. The position peaked at $76K in Q3 2016. 26 funds tracked by Wall St. Rank hold SYRE as of Q4 2016.

TLP Group reported no remaining Spyre Therapeutics position as of Q4 2016 after selling out during the quarter.
TLP Group sold 477 Spyre Therapeutics shares in Q4 2016, an estimated $76K.
TLP Group first reported a position in Spyre Therapeutics in Q3 2016 and held it in 1 quarter.
TLP Group's Spyre Therapeutics position peaked at $76K in Q3 2016.
26 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2016.

Based on TLP Group's 13F filing for Q4 2016, filed 2 Feb 2017.